Cargando…

VEGF and VEGFR2 bind to similar pH-sensitive sites on fibronectin, exposed by heparin-mediated conformational changes

Physical interactions between vascular endothelial growth factor (VEGF), a central player in blood endothelial cell biology, and fibronectin, a major fibrillar protein of the extracellular matrix, are important determinants of angiogenic activity in health and disease. Conditions signaling the need...

Descripción completa

Detalles Bibliográficos
Autores principales:	Usuelli, Mattia, Meyer, Timmy, Mezzenga, Raffaele, Mitsi, Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Biochemistry and Molecular Biology 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102423/ https://www.ncbi.nlm.nih.gov/pubmed/33771558 http://dx.doi.org/10.1016/j.jbc.2021.100584

Ejemplares similares

Heparin-binding VEGFR1 variants as long-acting VEGF inhibitors for treatment of intraocular neovascular disorders
por: Xin, Hong, et al.
Publicado: (2021)

Rho-mediated Contractility Exposes a Cryptic Site in Fibronectin and Induces Fibronectin Matrix Assembly
por: Zhong, Cuiling, et al.
Publicado: (1998)

VEGF-VEGFR Signals in Health and Disease
por: Shibuya, Masabumi
Publicado: (2014)

Transglutaminase-2 Interaction with Heparin: IDENTIFICATION OF A HEPARIN BINDING SITE THAT REGULATES CELL ADHESION TO FIBRONECTIN-TRANSGLUTAMINASE-2 MATRIX
por: Lortat-Jacob, Hugues, et al.
Publicado: (2012)

Rapamycin suppresses angiogenesis and lymphangiogenesis in melanoma by downregulating VEGF-A/VEGFR-2 and VEGF-C/VEGFR-3 expression
por: Wang, Min, et al.
Publicado: (2019)

Changes in the Expression Profile of VEGF-A, VEGF-B, VEGFR-1, VEGFR-2 in Different Grades of Endometrial Cancer
por: Dziobek, Konrad, et al.
Publicado: (2019)

Targeting VEGF/VEGFR to Modulate Antitumor Immunity
por: Yang, Ju, et al.
Publicado: (2018)

Diagnostic Value of VEGF-A, VEGFR-1 and VEGFR-2 in Feline Mammary Carcinoma
por: Nascimento, Catarina, et al.
Publicado: (2021)

VEGF-dependent tumor angiogenesis requires the inverse and reciprocal regulation of VEGFR1 and VEGFR2
por: Zhang, Zhaocheng, et al.
Publicado: (2009)

Oat Plant Amyloids for Sustainable Functional Materials
por: Zhou, Jiangtao, et al.
Publicado: (2021)

Genetic variations in VEGF and VEGFR2 and glioblastoma outcome
por: Sjöström, S., et al.
Publicado: (2010)

Counterbalance: modulation of VEGF/VEGFR activities by TNFSF15
por: Yang, Gui-Li, et al.
Publicado: (2018)

The VEGF/VEGFR Axis Revisited: Implications for Cancer Therapy
por: Mabeta, Peace, et al.
Publicado: (2022)

Structure-Based Design of Peptides Targeting VEGF/VEGFRs
por: Di Stasi, Rossella, et al.
Publicado: (2023)

Autolysin mediated adherence of Staphylococcus aureus with Fibronectin, Gelatin and Heparin
por: Porayath, Chandni, et al.
Publicado: (2018)

Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells
por: Garvin, S, et al.
Publicado: (2005)

A peptide mimicking the binding sites of VEGF-A and VEGF-B inhibits VEGFR-1/-2 driven angiogenesis, tumor growth and metastasis
por: Farzaneh Behelgardi, Maryam, et al.
Publicado: (2018)

Acidic pH reduces VEGF-mediated endothelial cell responses by downregulation of VEGFR-2; relevance for anti-angiogenic therapies
por: Faes, Seraina, et al.
Publicado: (2016)

The role of the VEGF-C/VEGFR-3 axis in cancer progression
por: Su, J-L, et al.
Publicado: (2007)

The Role of the VEGF-C/VEGFRs Axis in Tumor Progression and Therapy
por: Chen, Jui-Chieh, et al.
Publicado: (2012)

Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward?
por: Li, Yu-Ling, et al.
Publicado: (2016)

VEGF-A splice variants bind VEGFRs with differential affinities
por: Mamer, Spencer B., et al.
Publicado: (2020)

Inhibition of FGF‐FGFR and VEGF‐VEGFR signalling in cancer treatment
por: Liu, Guihong, et al.
Publicado: (2021)

Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer
por: Bando, H, et al.
Publicado: (2005)

Profiling of VEGFs and VEGFRs as Prognostic Factors in Soft Tissue Sarcoma: VEGFR-3 Is an Independent Predictor of Poor Prognosis
por: Kilvaer, Thomas K., et al.
Publicado: (2010)

Fibroblast cellular and plasma fibronectins are similar but not identical
Publicado: (1979)

BB0347, from the Lyme Disease Spirochete Borrelia burgdorferi, Is Surface Exposed and Interacts with the CS1 Heparin-Binding Domain of Human Fibronectin
por: Gaultney, Robert A., et al.
Publicado: (2013)

VEGFR-2 conformational switch in response to ligand binding
por: Sarabipour, Sarvenaz, et al.
Publicado: (2016)

Seasonal expressions of VEGF and its receptors VEGFR1 and VEGFR2 in the prostate of the wild ground squirrels (Spermophilus dauricus)
por: Yao, Yuchen, et al.
Publicado: (2021)

Phosphorylated fibronectin enhances cell attachment and upregulates mechanical cell functions
por: Yalak, Garif, et al.
Publicado: (2019)

RGD-independent cell adhesion to the carboxy-terminal heparin-binding fragment of fibronectin involves heparin-dependent and -independent activities
Publicado: (1990)

Expressions of VEGF-A and VEGFR-2 in placentae from GDM pregnancies
por: Meng, Qian, et al.
Publicado: (2016)

Pericytes regulate VEGF-induced endothelial sprouting through VEGFR1
por: Eilken, Hanna M., et al.
Publicado: (2017)

Molecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2
por: Peach, Chloe J., et al.
Publicado: (2018)

Risk of Dyslipidemia Associated with VEGF/VEGFR Inhibitors: A Meta-Analysis
por: Dai, Huihui, et al.
Publicado: (2020)

Dynamics of integrin α5β1, fibronectin, and their complex reveal sites of interaction and conformational change
por: Su, Yang, et al.
Publicado: (2022)

Lymphocyte CD44 binds the COOH-terminal heparin-binding domain of fibronectin
Publicado: (1992)

Multi-length scale structural investigation of lysozyme self-assembly
por: Catalini, Sara, et al.
Publicado: (2022)

Glycation of fibronectin inhibits VEGF‐induced angiogenesis by uncoupling VEGF receptor‐2‐c‐Src crosstalk
por: Chen, Tangting, et al.
Publicado: (2020)

Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models
por: Dev, I K, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_b0aiu441mb8dgud3tejpjao1jn